Targeted therapy and immunotherapy for orbital and periorbital tumors: a major review
- 2 September 2023
- journal article
- review article
- Published by Taylor & Francis in Orbit
- Vol. 43 (5) , 656-673
Abstract
Traditionally, for patients who are poor candidates for surgery and/or radiotherapy, palliative chemotherapy is often offered but with significant toxic side effects. However, recent advancements in our understanding of tumor biology and molecular genetics have brought new understanding to the molecular pathways of certain tumors and cancers. This has ushered in a new era of precision medicine specific to a tumor or cancer treatment pathway (targeted therapy) or directed to host-tumor responses (immunotherapy). This article will focus on recent updates in the application of available targeted and immunotherapy for managing orbital and periorbital tumors and tumor-like conditions, which include cutaneous basal cell carcinoma, cutaneous squamous cell carcinoma, cutaneous melanoma, Merkel cell carcinoma, sebaceous gland carcinoma, solitary fibrous tumor, dermatofibrosarcoma protuberans, orbital meningioma, neurofibromatosis, Langerhans cell histiocytosis, ocular adnexal lymphoma, orbital lymphatic malformation, and adenoid cystic carcinoma.Keywords
Funding Information
- funding associated
This publication has 150 references indexed in Scilit:
- Targeted Therapy for Orbital and Periocular Basal Cell Carcinoma and Squamous Cell CarcinomaOphthalmic Plastic & Reconstructive Surgery, 2013
- The role of BRAF V600 mutation in melanomaJournal of Translational Medicine, 2012
- Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated byNRASorMEKMutationsMolecular Cancer Therapeutics, 2012
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with VemurafenibNew England Journal of Medicine, 2012
- Inhibition of Mutated, Activated BRAF in Metastatic MelanomaNew England Journal of Medicine, 2010
- Imatinib Mesylate as a Preoperative Therapy in Dermatofibrosarcoma: Results of a Multicenter Phase II Study on 25 PatientsClinical Cancer Research, 2010
- Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed Malignant Haemangioperyctoma /Solitary Fibrous TumourInvestigational New Drugs, 2009
- Correlations between the Sonic Hedgehog Pathway and basal cell carcinomaInternational Journal of Dermatology, 2007
- Sonic hedgehog signaling by the Patched–Smoothened receptor complexCurrent Biology, 1999
- CD20: a regulator of cell-cycle progression of B lymphocytesImmunology Today, 1994